Research programme: cedar pollen allergy immunotherapy - REGiMMUNE

Drug Profile

Research programme: cedar pollen allergy immunotherapy - REGiMMUNE

Alternative Names: RGI-1001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REGiMMUNE
  • Class Antigens
  • Mechanism of Action Immunomodulators; Natural killer T cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Japan
  • 28 Feb 2014 REGiMMUNE's cedar pollen allergy immunotherapy programme is available for licensing in World (excluding Japan) as of 28 Feb 2014. http://www.regimmune.com/
  • 18 Jul 2011 Preclinical development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top